|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Study | Participant Characteristics | Intervention; Duration | Discontinuation | Serious Adverse Events | Other Adverse Events | Quality Rating |
| Greenspan et. al, 200736 | Postmenopausal women with mean age of 64.4 years; T-score ≤ -3.0; no prevalent vertebral fractures or T-score -2.5 with 1 to 4 vertebral fractures; mean T-score -2.2; 19% with prior vertebral fracture | Parathyroid hormone 100 µg daily injection; 18 months | 389/1286 (100 ug);  306/1246 (placebo)  RR 1.22 (1.08-1.40) | None reported | 291/1286; 114/1246  RR: 2.47 (2.02-3.03) | Fair |
| Orwoll et. al, 2003240 | Men with mean age 59 years; mean T-score  -2.7; unknown prior fracture | Teriparatide 20 µg or  40 µg daily injection; mean treatment duration: 11 months | 14/151 (20 ug)  18/139 (40 ug)  7/147 (placebo)  RR: 1.94 (0.81-4.69)  RR: 2.72 (1.17-6.3) | Cancers  3/151 (20 ug)  0/139 (40 ug)  3/147 (placebo)  RR: 0.97 (0.2-4.74)  RR: 0.15 (0.008-2.9) | Nausea  0/151  5/139  0/147 | Fair |

**Abbreviations:** RR=risk ratio; ug=micrograms.